Anthropic and Novartis are collaborating on preclinical drug discovery programs, while the rivalry between AI firms drives market focus.

The entities involved

• Anthropic →

  American artificial intelligence corporation

  • The European Commission aims to strengthen homegrown AI capabilities while global advanced models face usage restrictions.Mon 17:49
  • An administration order issued by the Trump administration on January 1, 2026, cited national security concerns regarding Anthropic.Mon 17:49
• Novartis →

  Swiss-American multinational pharmaceutical corporation

  • Novartis acquired Avidity in a $12 billion purchase, while Trump simultaneously threatened Swiss businesses with tariffs.Sat 01:46
  • GSK and Novartis are identified as major pharmaceutical companies.Fri 02:16
• OpenAI →

  American artificial intelligence research organization

  • Leaders call for international cooperation on AI risks, tech leaders call for oversight, and the CMA proposes stricter search engine choice requirements.Mon 17:41
  • Experts, including Dario Amodei at Cornell University, warned about the power and limits of AI, specifically citing risks of AI taking control of the internet.Mon 17:41

Related events

• Eli Lilly and Company is collaborating with Nvidia and OpenAI to build an AI lab aimed at accelerating drug discovery.Jun 19
• OpenAI and Anthropic announced a partnership to use Claude models in R&D, while Novo Nordisk and Eli Lilly intensify competition in the obesity drug market.Sep 22
• Anthropic and OpenAI are recognized as leading companies in the field of AI development.Jun 22
• Safe Superintelligence Inc. and OpenAI are recognized as high-stakes AI ventures.Aug 18
• The competitive landscape of advanced AI is highlighted by the race among major labs (OpenAI, Google, Anthropic) to build powerful models and the movement of key researchers.Jun 20